Somatic Test
prev next

HRR Somatic

Targeting Deficient Homologous Recombination Repair
line
Homologous Recombination is a type of genetic recombination in which genetic information is exchanged between two similar or identical molecules of double-stranded nucleic acids. line
Homologous Recombination Repair (HRR) is a double-strand break DNA repair process that aids in maintaining genomic integrity. Mutations leading to Homologous Recombination Deficiency (HRD) increase the tumor sensitivity to platinum-based chemotherapy and PARP inhibitors. line
The HRR (Somatic) Cancer Gene Panel focuses on 15 genes (including BRCA1 and BRCA2) associated with DNA repair mechanisms to determine the cause of Deficient Homologous Recombination Repair (dHRR) cancers. Guidelines recommend HRR Somatic gene panel testing to identify patients who will benefit from PARP inhibitors. line

SNVs/InDels & CNAs Coverage in HRR (Somatic)
HRR Somatic Gene Panel List :

ATM BARD1 BRCA1 BRCA2 BRIP1 CDK12 CHEK1 CHEK2
FANCL PALB2 PPP2R2A RAD51B RAD51C RAD51D RAD54L

Benefits of HRR (Somatic) Gene Panel Testing

Personalized treatment decisions

The information provided by this gene panel testing allows for personalized treatment decisions based on the genomic characteristics of the tumor. This approach improves treatment outcomes by selecting therapies that are more likely to be effective and minimizing the use of treatments that are unlikely to provide benefit.

Predicting treatment response

Patients with dHRR cancers, characterized by HRD-associated mutations, often exhibit increased sensitivity to specific treatments. By identifying these mutations through this gene panel test, oncologists can predict the patient’s potential response to these targeted therapies.

Guiding the use of PARP inhibitors

This gene panel testing helps identify patients with dHRR cancers, making them potential candidates for PARP inhibitor therapy. This targeted approach improves treatment outcomes by directing patients toward therapies that are more likely to be effective.

Clinical guidelines recommendation

This gene panel testing is recommended by clinical guidelines for identifying patients who will benefit from PARP inhibitors. These guidelines are evidence-based recommendations developed by field experts designed to optimize patient care.

Why Choose 4baseCare's HRR (Somatic) Cancer Gene Panel?

Comprehensive Analysis

Our Cancer Gene Panel thoroughly assesses clinically relevant genes, ensuring accurate and reliable results.

Advanced Technology

We utilize cutting-edge genomic sequencing technologies to deliver precise and detailed genetic information.

Expert Team

Our team of experienced genetic counselors and healthcare professionals will guide you through the testing process, answer your questions, and help you understand the implications of the results.

Confidentiality and Privacy

We adhere to strict privacy protocols and maintain the confidentiality of your genetic information.

download
Downloads
book
Book your Test
loader